Targovax and Valo Therapeutics Enter Collaboration to Develop RAS Neoantigen Coating of ONCOS Viruses Using PeptiCRAd Technology |
| April 22, 2020 | April 2020 Bond Updates |
|
OSLO, Norway, and HELSINKI, April 22, 2020 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses and cancer vaccines to target hard-to-treat solid tumors, and Valo Therapeutics (Valo Tx) today announce that they have entered into a... |
| View more at: https://www.prnewswire.com:443/news-releases/targovax-and-valo-therapeutics-enter-collaboration-to-develop-ras-neoantigen-coating-of-oncos-viruses-using-pepticrad-technology-301044964.html |
| Related News |